Peer-influenced content. Sources you trust. No registration required. This is HCN.
DocWire News
The study’s findings suggest a potential paradigm shift in the management of cancer patients with isolated distal DVT. With the 12-month edoxaban regimen reducing the occurrence of the primary composite endpoint to just 1.0% compared to 7.2% in the three-month group, this could represent a significant advancement in patient care.
Hematology November 6th 2023
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH 